Incyte Corporation (Nasdaq:INCY) announced today that Richard Levy, M.D., senior vice president, drug development of Incyte will present at the Punk, Ziegel & Company's Investor Symposium, New Agents to Treat HIV, on Monday, November 22, 2004 at 10:50 a.m. (ET).

The presentation will be webcast live and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the presentation will be available until February 22, 2005.

About Incyte

Incyte Corporation is a Wilmington, Delaware based drug discovery and development company with a growing pipeline of oral compounds to treat HIV, inflammation, cancer and diabetes. The company's most advanced product candidate, Reverset(TM), is an oral, once-a-day therapy in Phase II clinical trials to treat patients with HIV infections. The company's lead internal compound, INCB3284, is a proprietary, oral CCR2 antagonist in Phase I development that may have therapeutic value in a number of chronic inflammatory diseases. Incyte has several other early drug discovery programs underway and a proteomic information business based in Beverly, Massachusetts.

Except for the historical information contained herein, the matters set forth in this press release, including the expected utility of the company's product candidates, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including developments affecting Incyte's research and development activities, the results of further research and development, and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the three months ended September 30, 2004. Incyte disclaims any intent or obligation to update these forward-looking statements.